Bitte beachten Sie: Suchbegriffe unter einer Länge von 3 Buchstaben werden ignoriert.
267 Treffer:
31.
A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 fol
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Non-Hodgkin-Lymphome (incl. CLL)
Datum: 2026-04-04
32.
Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induc
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Non-Hodgkin-Lymphome (incl. CLL)
Datum: 2026-04-04
33.
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-04-04
34.
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalido
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-04-04
35.
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Multiples Myelom
Datum: 2026-04-04
36.
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematolo
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute myeloische Leukämie
Datum: 2026-04-04
37.
Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute myeloische Leukämie
Datum: 2026-04-04
38.
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute myeloische Leukämie
Datum: 2026-04-04
39.
Sequential Gilteritinib in Combination With Venetoclax and Azacitidine for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and FLT3 Mutations Ineligible for Intensive Treatment.
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute myeloische Leukämie
Datum: 2026-04-04
40.
A Multicentre, Randomized Trial in Adults With de Novo Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia to Assess the Efficacy of Ponatinib Versus Imatinib in Combination With Low-intensity Chemotherapy, to Compare End of Therapy With Indicat
NCT Heidelberg » Für Ärzte » Studien » Hämatologische Neoplasien » Akute lymphatische Leukämie
Datum: 2026-04-04